The Significance of Various Factors Associated with Hemorrhagic Transformation in Patients Treated with Recombinant Tissue Plasminogen Activator for Acute Stroke

  • M. S. Pessin
  • S. M. Wolpert
Conference paper

Abstract

Intracranial bleeding is the principal safety concern and use-limiting factor related to the application of thrombolytic agents in acute stroke. Several recent studies, using intravenously administered recombinant tissue plasminogen activator (rt-PA) for carotid and vertebrobasilar territory stroke, have documented intracranial bleeding in the form of hemorrhagic infarction (HI) and parenchymatous hematoma (PH) [2, 4, 11, 16, 19]. That intracranial bleeding is not limited to the use of thrombolytic agents in stroke patients has been amply documented in studies of patients with acute myocardial infarction treated with these agents where a small but consistent incidence has been noted in the range of approximately 0.5% (Table 1) [6, 7, 9, 10, 14, 15, 18]. The purpose of this discussion is to examine several factors presumed to be associated with intracranial bleeding in stroke patients treated with thrombolytic agents using data from the rt-PA Acute Stroke Study Group trial [4] and other recent trials [2, 8, 11, 16, 19]. A preview of this analysis suggests that many of the long and firmly held views regarding influences and effects of hemorrhagic transformation (HT) are not supported by recent information.

Keywords

Ischemia Aspirin Heparin Warfarin Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bozzao L, Angeloni U, Bastianello S, Fantozzi LM, Pierallini A, Fieschi C (1991) Early angiographic and CT findings in patients with hemorrhagic infarction in the distribution of the middle cerebral artery. AJNR 12:1115–1121PubMedGoogle Scholar
  2. 2.
    Brott TG, Haley EC, Levy DE, et al (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plaminogen activator administered within 90 minutes. Stroke 23:632–640PubMedCrossRefGoogle Scholar
  3. 3.
    Cerebral Embolism Study Group (1984) Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options. Stroke 15:779–789CrossRefGoogle Scholar
  4. 4.
    del Zoppo GJ, Poeck K, Pessin MS, and 16 coauthors of the rt-PA Acute Stroke Study Group (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32:78–86PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher CM, Adams RD (1951) Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 10:92–94PubMedGoogle Scholar
  6. 6.
    Gore JM, Sloan M, Price TR, et al (1991) Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in myocardial infarction, Phase II, pilot and clinical trial. Circulation 83:448–459PubMedGoogle Scholar
  7. 7.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (1990) GISSI-2: A factorial randomised trial of alteplace versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 336:65–71Google Scholar
  8. 8.
    Haley EC, Levy DE, Brott TG, et al (1992) Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23:641–645PubMedCrossRefGoogle Scholar
  9. 9.
    International Study Group (1992) In-hospital mortality and clinical course of 20, 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 536:71–75Google Scholar
  10. 10.
    Kase CS, Pessin MS, Zivin JA, et al (1992) Intracranial hemorrhage following coronary thrombolysis with tissue plasminogen activator. Am J Med 92:384–390PubMedCrossRefGoogle Scholar
  11. 11.
    Mori E, Yoneda Y, Tabuchi M, et al (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42:976–982PubMedGoogle Scholar
  12. 12.
    Ogata J, Yutani C, Imakita M, et al (1989) Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 20:876–883PubMedCrossRefGoogle Scholar
  13. 13.
    Okada Y, Yamaguchi T, Minematsu K, et al (1989) Hemorrhagic transformation in cerebral embolism. Stroke 20:598–603PubMedCrossRefGoogle Scholar
  14. 14.
    Sloan MA, Price TR (1991) Intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction. Semin Neurol 11:385–399PubMedCrossRefGoogle Scholar
  15. 15.
    Uglietta JP, O’Connor CM, Boyko OB, Aldrich H, Massey EW, Heinz ER (1991) CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. Radiology 181:555–559PubMedGoogle Scholar
  16. 16.
    von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery. Stroke 23:646–652CrossRefGoogle Scholar
  17. 17.
    Warach S, Chien D, Li W, Ronthal M, Edelman RR (1992) Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 42:1717–1723PubMedGoogle Scholar
  18. 18.
    Wilcox RG, Olsson CG, Skene AM, et al (1988) Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2:525–530PubMedCrossRefGoogle Scholar
  19. 19.
    Yamaguchi T, Hayakawa T, Kikuchi H, Abe T (1991) Thrombolytic therapy in embolic and thrombotic cerebral infarction: A cooperative study. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute stroke. Springer-Verlag, Berlin Heidelberg New York, p 168Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. S. Pessin
    • 1
  • S. M. Wolpert
    • 2
  1. 1.Department of NeurologyTufts University School of Medicine, New England Medical CenterBostonUSA
  2. 2.Department of Radiology (Division of Neuroradiology)Tufts University School of Medicine, New England Medical CenterBostonUSA

Personalised recommendations